4D Path Presents Breakthrough Research Demonstrating That Its Unique Digital Predictive Biomarker Identifies Treatment Responders in a Difficult-To-Treat Breast Cancer Patient Population
QPOR™ platform delivers unprecedented predictive insights for patients with low immune infiltrates—achieving a 66% response rate vs. 25% with conventional methods Newton, Massachusetts –…